Global drinks can manufacturer Rexam has agreed to sell its pharmaceutical devices and prescription retail packaging units to Montagu Private Equity for $805m.
The two business units employed 1,500 people and recorded sales of £250m in 2012.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The transaction is subject to consultation with several European works councils. It would be completed in mid-2014.
Rexam plans to return approximately £450m to shareholders from the sale through a redeemable B share scheme along with a share consolidation.
Rexam CEO Graham Chipchase said that the sale of its healthcare business divisions is part of a plan to maximise shareholder value.
"The pharmaceutical devices and prescription retail packaging divisions represent the majority of the value of our healthcare business," Chipchase added.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"Following the sale of healthcare, we will be a focused beverage cans business with a strong financial position."
Rexam is also holding talks regarding the sale of its closures and containers division, which makes plastic bottles for over-the-counter medicine.
